SYBRAVA 284 mg Injection SYBRAVA contains Inclisiran, a synthetic small interfering ribonucleic acid (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc) to facilitate targeted uptake by hepatocytes. Inclisiran utilizes the natural RNA interference (RNAi) mechanism to direct the catalytic degradation of proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA. By suppressing intracellular PCSK9 translation, it increases LDL-receptor recycling and expression on the hepatocyte membrane, thereby significantly lowering circulating low-density lipoprotein cholesterol (LDL-C) levels. It is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia.